Provention Bio (NASDAQ:PRVB) has observed the following analyst ratings within the last quarter: These 4 analysts have an average price target of $22.75 versus the current price of Provention Bio at ...

Provention Bio, a biopharmaceutical company based in Red Bank, recently announced the closing of a $35 million equity investment from Bridgewater-based Sanofi US. The deal is part of a previously ...

Following Sanofi‘s $35 million equity investment last month, the global health care company will acquire Red Bank-based Provention Bio Inc. for $25 per share, representing an equity value of ...

-If Approved Teplizumab will be the First Disease-Modifying Therapy for Type 1 Diabetes - Certain statements in this press release are forward-looking, including but not limited to, statements ...

The U.S. antitrust watchdog is taking more time to review the proposed combination of Sanofi and Provention Bio, two diabetes drug developers. Meanwhile, all eyes in biopharma are on the merger ...

Provention Bio Inc (NASDAQ:PRVB) shares are trading higher by 20.6% to $5.97 Thursday morning after the company announced it has entered into a co-promotion agreement with Sanofi U.S. for the launch ...

Provention Bio Inc (NASDAQ:PRVB) shares are rocketing higher Monday after Sanofi (NASDAQ:SNY) announced plans to acquire the biopharmaceutical company. What Happened: Sanofi and Provention Bio entered ...

Every investor in Provention Bio, Inc. (NASDAQ:PRVB) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders ...

Sanofi proposed to acquire Provention Bio for $2.9 billion in cash at a 273% premium over the previous closing price (before the deal announcement). The acquisition is expected to be a net positive ...

Provention Bio's leading candidate and exciting pipeline show real potential. But the biotech could face clinical, regulatory, and funding problems. The headwinds related to teplizumab have played a ...

Sanofi SA said Monday that it has entered into an agreement to acquire U.S.-based biopharmaceutical company Provention Bio, Inc. for around $2.9 billion, or $25 a share. The French pharma major said ...

Things can change quickly in the volatile biotech industry. Just ask Provention Bio (NASDAQ: PRVB). The autoimmune disease-focused drugmaker seemed on the verge of earning a major regulatory approval ...